Industry: Pharmaceuticals, Biotechnology
Antipodean is a clinical-stage pharmaceutical company developing treatments for Parkinson’s Disease, Friedreich ataxia, and other disorders associated with mitochondrial dysfunction. The company’s lead product, MitoQ, has started Phase 2 trials in Parkinson’s disease and will soon be studied in Friedreich ataxia. No curative or disease modifying therapies exist for either disease. Antipodean recently opened its corporate headquarters in San Francisco, California and maintains an operational base in Auckland, New Zealand. The company is continuing to work closely with researchers and investigators in New Zealand and Australia as well as in the Bay Area and elsewhere in the US to develop MitoQ and other therapeutics based on mitochondrial
Antipodean Pharmaceuticals Inc.
1700 Montgomery Street (Map/Directions) Suite 209
San Francisco, California 94111
USA
Tel: (415) 692-0610
Fax: (415) 692-0620